AR121857A1 - Anticuerpo anti-ox40 y usos del mismo - Google Patents

Anticuerpo anti-ox40 y usos del mismo

Info

Publication number
AR121857A1
AR121857A1 ARP210101006A ARP210101006A AR121857A1 AR 121857 A1 AR121857 A1 AR 121857A1 AR P210101006 A ARP210101006 A AR P210101006A AR P210101006 A ARP210101006 A AR P210101006A AR 121857 A1 AR121857 A1 AR 121857A1
Authority
AR
Argentina
Prior art keywords
antibody
seq
indicated
amino acid
acid sequence
Prior art date
Application number
ARP210101006A
Other languages
English (en)
Inventor
Yizhen Yang
Yu Cai
Xiong Li
Lei Zhou
Weiguo Qing
Wei-Guo Su
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of AR121857A1 publication Critical patent/AR121857A1/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)

Abstract

Reivindicación 1: Un anticuerpo anti-OX40 aislado, que comprende (1) regiones determinantes de la complementariedad de cadena pesada (HCDRs), HCDR1, HCDR2 y HCDR3, donde la HCDR1 comprende la secuencia de aminoácidos como se indica en la SEQ ID Nº 11, la HCDR2 comprende la secuencia de aminoácidos como se indica en la SEQ ID Nº 12, y la HCDR3 comprende la secuencia de aminoácidos como se indica en la SEQ ID Nº 13; (2) regiones determinantes de la complementariedad de cadena liviana (LCDRs), LCDR1, LCDR2 y LCDR3, donde la LCDR1 comprende la secuencia de aminoácidos como se indica en la SEQ ID Nº 14, la LCDR2 comprende la secuencia de aminoácidos como se indica en la SEQ ID Nº 15, y la LCDR3 comprende la secuencia de aminoácidos como se indica en la SEQ ID Nº 16; y (3) una variante de región Fc, la cual es IgG1 N297A humana. Reivindicación 7: Un ácido nucleico aislado que codifica el anticuerpo de cualquiera de las reivindicaciones 1 - 6. Reivindicación 10: Un inmunoconjugado o una fusión inmune, que comprende el anticuerpo de cualquiera de las reivindicaciones 1 - 6. Reivindicación 12: Uso del anticuerpo de cualquiera de las reivindicaciones 1 - 6, el ácido nucleico de la reivindicación 7, el vector de la reivindicación 8, la célula huésped de la reivindicación 9, o el inmunoconjugado o la fusión inmune de la reivindicación 10 en la manufactura de un medicamento para tratar o prevenir una enfermedad o condición relacionada con OX40. Reivindicación 16: Un método para detectar OX40 en una muestra que comprende: (a) contactar la muestra con el anticuerpo de cualquiera de las reivindicaciones 1 - 6 o el inmunoconjugado o la fusión inmune de la reivindicación 10; y b) detectar la formación del complejo del anticuerpo o el inmunoconjugado o la fusión inmune con la proteína OX40.
ARP210101006A 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo AR121857A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010304381 2020-04-17

Publications (1)

Publication Number Publication Date
AR121857A1 true AR121857A1 (es) 2022-07-20

Family

ID=78084656

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP210101007A AR121858A1 (es) 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo
ARP210101006A AR121857A1 (es) 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP210101007A AR121858A1 (es) 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo

Country Status (15)

Country Link
US (3) US20230242657A1 (es)
EP (2) EP4136116A4 (es)
JP (2) JP2023523395A (es)
KR (2) KR20230015327A (es)
CN (2) CN115461367A (es)
AR (2) AR121858A1 (es)
AU (2) AU2021256799A1 (es)
BR (2) BR112022020741A2 (es)
CA (2) CA3175407A1 (es)
CL (2) CL2022002829A1 (es)
IL (2) IL297294A (es)
MX (2) MX2022012915A (es)
PE (2) PE20230682A1 (es)
TW (2) TW202144424A (es)
WO (2) WO2021209020A1 (es)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SI2851374T1 (sl) 2007-12-14 2017-08-31 Bristol-Myers Squibb Company Vezavne molekule k humanemu ox40 receptorju
PE20142243A1 (es) * 2011-07-11 2015-01-11 Glenmark Pharmaceuticals Sa Anticuerpos que se unen a ox40 y sus usos
CN104968364A (zh) * 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
PL3126394T3 (pl) * 2014-03-31 2020-05-18 F.Hoffmann-La Roche Ag Przeciwciała anty-OX40 i sposoby stosowania
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗-ox40抗體及其用途
CA2984794A1 (en) * 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2018027204A1 (en) * 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US11242398B2 (en) 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
JP2021501801A (ja) * 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 癌の処置に用いるための免疫刺激アゴニスト抗体
SG11202003443TA (en) * 2017-11-24 2020-05-28 Eucure Beijing Biopharma Co Ltd Anti-ox40 antibodies and uses thereof
CN111393529B (zh) * 2018-01-29 2022-02-22 康源博创生物科技(北京)有限公司 与ox40l非竞争结合的抗ox40抗体
CN111936507B (zh) * 2018-03-23 2022-11-01 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
SG11202011024WA (en) 2018-05-23 2020-12-30 Beigene Ltd Anti-ox40 antibodies and methods of use

Also Published As

Publication number Publication date
KR20230015328A (ko) 2023-01-31
KR20230015327A (ko) 2023-01-31
TW202144424A (zh) 2021-12-01
WO2021209019A1 (en) 2021-10-21
CL2022002830A1 (es) 2023-06-09
CA3175407A1 (en) 2021-10-21
MX2022012915A (es) 2022-11-16
US20230242657A1 (en) 2023-08-03
CN115461366A (zh) 2022-12-09
EP4136117A1 (en) 2023-02-22
MX2022012913A (es) 2022-11-14
CN115461367A (zh) 2022-12-09
AU2021256799A1 (en) 2022-11-17
IL297292A (en) 2022-12-01
EP4136117A4 (en) 2024-04-10
EP4136116A1 (en) 2023-02-22
IL297294A (en) 2022-12-01
AR121858A1 (es) 2022-07-20
WO2021209020A1 (en) 2021-10-21
BR112022020741A2 (pt) 2022-12-20
TW202144423A (zh) 2021-12-01
BR112022020742A2 (pt) 2022-12-20
PE20230682A1 (es) 2023-04-21
AU2021256226A1 (en) 2022-11-17
US12030951B2 (en) 2024-07-09
US20240301077A1 (en) 2024-09-12
PE20230255A1 (es) 2023-02-07
JP2023523395A (ja) 2023-06-05
EP4136116A4 (en) 2024-06-19
US20230151105A1 (en) 2023-05-18
CL2022002829A1 (es) 2023-06-09
JP2023521475A (ja) 2023-05-24
CA3175413A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
CO6230999A2 (es) Anticuerpo anti-esclerostina
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20190630A1 (es) Anticuerpos de anti-tim-3
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PE20231049A1 (es) Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
CO6180431A2 (es) Anticuerpos e inmunoconjugados y sus usos
AR123083A1 (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
AR069062A1 (es) Anticuerpo anti-hepcidina
PE20240363A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
CO2018001256A2 (es) Anticuerpos anti-cd154 y métodos para producir los mismos
PE20091351A1 (es) Anticuerpos humanizados especificos para el factor von willebrand
AR112341A1 (es) ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
BR112018011270A2 (pt) anticorpo isolado, composição farmacêutica, e, métodos para tratamento ou redução da taxa de recorrência de um câncer em um paciente e para detecção de células tronco do câncer.
RU2018120695A (ru) Связывающие молекулы, специфичные в отношении asct2, и их применения
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
PE20201494A1 (es) Anticuerpo anti-pacap